Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is injected once weekly and is being tested in type 2 diabetes and obesity .

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Nov 18, 2024 · What is CagriSema? CagriSema is an experimental drug being developed by Novo Nordisk. It is currently undergoing late-stage clinical trials for the treatment of obesity and type 2 diabetes.

Jul 17, 2023 · CagriSema is a once-weekly injection of semaglutide and cagrilintide. CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes and weight management treatment.

Dec 26, 2024 · CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), that works by decreasing hunger and...

Jan 2, 2025 · CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), that works by decreasing hunger and increasing the feeling of fullness.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, increasing feelings of fullness and thereby help people eat less and reduce their calorie intake.

Aug 26, 2023 · We found that treatment with co-administered semaglutide 2·4 mg and cagrilintide 2·4 mg (CagriSema) resulted in clinically relevant improvements in glycaemic control, including continuous glucose monitoring parameters, as well as significantly greater weight loss than either semaglutide or cagrilintide alone.

Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...

Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide.